A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan (NCT07196644)
A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification
🩺 Plain-English Summary (8th-Grade Level)
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of locally advanced or metastatic solid tumors that harbor MET amplification. This study will have 1 arm where participants will receive telisotuzumab adizutecan. Approximately 100 participants 12 years of age or older. with solid tumors harboring MET amplification will be enrolled in the study in up to 50 sites around the world. Participants will receive intravenous (IV) telisotuzumab adizutecan, as part of the 61.5 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Who can join: Review the eligibility criteria below.
Location: Beverly Hills Cancer Center /ID# 275465 — Beverly Hills, California
Age range: 12 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (38 Sites)
Showing the first 25 of 38 sites.
- Beverly Hills Cancer Center /ID# 275465 — Beverly Hills, California
- City of Hope National Medical Center /ID# 275613 — Duarte, California
- Valkyrie Clinical Trials /ID# 275547 — Los Angeles, California
- Stanford University - Palo Alto /ID# 282083 — Palo Alto, California
- Yale University School of Medicine /ID# 275978 — New Haven, Connecticut
- Florida Cancer Specialists - North /ID# 277137 — St. Petersburg, Florida
- Northwestern University Feinberg School of Medicine /ID# 276436 — Chicago, Illinois
- University of Chicago Medical Center /ID# 275342 — Chicago, Illinois
- START Midwest /ID# 276603 — Grand Rapids, Michigan
- Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 275999 — New York, New York
- Duke Cancer Institute /ID# 275604 — Durham, North Carolina
- SCRI Oncology Partners /ID# 275686 — Nashville, Tennessee
- Dell Seton Medical Center /ID# 276474 — Austin, Texas
- University of Texas - Southwestern Medical Center /ID# 276053 — Dallas, Texas
- The University of Texas MD Anderson Cancer Center /ID# 275663 — Houston, Texas
- South Texas Accelerated Research Therapeutics /ID# 276608 — San Antonio, Texas
- Start Mountain Region /ID# 276607 — West Valley City, Utah
- Virginia Cancer Specialists - Fairfax /ID# 276010 — Fairfax, Virginia
- Rabin Medical Center. /ID# 274341 — Petah Tikva, Central District
- The Chaim Sheba Medical Center /ID# 274342 — Ramat Gan, Tel Aviv
- Tel Aviv Sourasky Medical Center /ID# 274344 — Tel Aviv, Tel Aviv
- Hadassah Medical Center-Hebrew University /ID# 274343 — Jerusalem,
- Nagoya University Hospital /ID# 276336 — Nagoya, Aichi-ken
- National Cancer Center Hospital East /ID# 276298 — Kashiwa-shi, Chiba
- Kyushu University Hospital /ID# 276302 — Fukuoka, Fukuoka
📞 Contact the Study Coordinator
Phone: (844) 663-3742
Email: abbvieclinicaltrials@abbvie.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Solid Tumors Harboring MET Amplification clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.